Abstract 90P
Background
Neutrophils (Nph) can play both protumor (N2) and antitumor (N1) roles at different stages of carcinogenesis. The tumor microenvironment promotes Nph polarization and enhances pro-angiogenic properties, contributing to changes in serum endothelial growth factor-A (VEGF-A) levels (Amorim C. et al., 2022).The aim of the study was to evaluate the ability of circulating neutrophils to produce VEGF-A during the progression of kidney cancer (KC).
Methods
The object of the study was the blood Nph of patients with KC before treatment, clear cell type I stage (T1N0M0G1, n=28, 60 years), II stage (T2N0M0G2, n=15, 61 years) and III stage (T3N0M0G2, n=15, 63 years) and the control group (n=15, 54 years). RNA was isolated from the peripheral blood Nph fraction on SileksMagNA magnetic particles (Sileks, Russia). The reverse transcription reaction was carried out and the expression of the VEGF-A gene was determined by quantitative PCR using primers (Evrogen, Russia). The level of VEGF-A in serum (pg/ml) was determined by ELISA (Vector-Best-Volga, Russia). The results are presented as Me (Q1-Q3). Statistical processing was performed in Statistica 13 (Mann–Whitney U test, Spearman correlation coefficient (p<0.05)). The study was approved by the Ethics Committee of IME&PK UlSU (protocol No. 1 of 01/15/2020).
Results
We found an increase in the serum level of VEGF-A at all stages of KC (stage I: 227.34 (227.34-399.49), p=0.002; stage II: 337.52 (329.33-692.18), p = 0.0005; III stage: 372.99 (282.99-545.82), p=0.001) relative to the control group (136.34 (91.01-168.95)). This may be due to the development of the angiogenic process during the progression of KC. The absolute amount of Nph decreased depending on the stage of KC: 4.6x109/l at stage I, 3.95x109/l - at stage III, 3.75x109/l - at stage IV. Expression of the VEGF-A gene by circulating Nph did not change at different stages of KC. However, at stage III KC, a correlation was found between VEGF-A gene expression in Nph and the level of this factor in serum (r=0.321, p=0.05).
Conclusions
Our results suggest that circulating Nph in KC has a high potential for VEGF-A production. At the same time, in stage III of KC, the serum level of VEGF-A is associated with an increased release of intracellular VEGF-A from Nph.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract